Development asset linked to Minoryx Therapeutics in public FDA and regional records.
pharma · Cerebral adrenoleukodystrophy (cALD) · Adrenoleukodystrophy
Minoryx Therapeutics
Minoryx Therapeutics S.L.
Minoryx Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
ES HQ
2011 Founded
32 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- ES
- Founded
- 2011
- Employees
- 32
- Programs
- 4
- Drugs
- 11
- Patents
- 0
Minoryx Therapeutics pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Minoryx Therapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.
-
Development asset linked to Minoryx Therapeutics in public FDA and regional records.